

Komorbiditäten in der Schlaganfallprophylaxe

Sichere Antikoagulation beim Patienten mit Vorhofflimmern und Metabolisch Vaskulärem Syndrom

T. Gaspar

Literatur

- [1] Hanefeld M, Leonhardt W: Das metabolische Syndrom. Dt Gesundheitswesen 1981; 36:545-551.
- [2] Hanefeld M, Koehler C, Gallo S, Benke I, Ott P: Impact of the individual components of the metabolic syndrome and their different combinations on the prevalence of atherosclerotic vascular disease in type 2 diabetes: the Diabetes in Germany (DIG) study. Cardiovasc Diabetol 2007;6:13.
- [3] Jacques Noubiap J, Richie Nansseu J, Lontchi-Yimagou E, René Nkeck J, Flore Nyaga U, Ngouo AT, Noelle Tounouga D, Leonel Tianyi F, Joyce Foka A, Laetitia Ndoadoumgue A, Joel Bigna J. Geographic distribution of metabolic syndrome and its components in the general adult population: a meta-analysis of global data from 28 million individuals. Diabetes Res Clin Pract. 2022 May 15
- [4] Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR, Cheng S, Das SR, Delling FN, Djousse L, Elkind MSV, Ferguson JF, Fornage M, Jordan LC, Khan SS, Kissela BM, Knutson KL, Kwan TW, Lackland DT, Lewis TT, Lichtman JH, Longenecker CT, Loop MS, Lutsey PL, Martin SS, Matsushita K, Moran AE, Mussolino ME, O'Flaherty M, Pandey A, Perak AM, Rosamond WD, Roth GA, Sampson UKA, Satou GM, Schroeder EB, Shah SH, Spartano NL, Stokes A, Tirschwell DL, Tsao CW, Turakhia MP, VanWagner LB, Wilkins JT, Wong SS, Virani SS, American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics 2019 update: a report from the American Heart Association. Circulation 2019;139:e56 e528
- [5] Staerk L, Sherer JA, Ko D, Benjamin EJ, Helm RH. Atrial fibrillation: epidemiology, pathophysiology, and clinical outcomes. Circ Res 2017;120:1501
- [6] Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, Boriani G, Castella M, Dan GA, Dilaveris PE, Fauchier L, Filippatos G, Kalman JM, La Meir M, Lane DA, Lebeau JP, Lettino M, Lip GYH, Pinto FJ, Thomas GN, Valgimigli M, Van Gelder IC, Van Putte BP, Watkins CL; ESC Scientific Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021 Feb 1;42(5):373-498. doi: 10.1093/eurheartj/ehaa612. Erratum in: Eur Heart J. 2021 Feb 1;42(5):507. Erratum in: Eur Heart J. 2021 Feb 1;42(5):546-547. Erratum in: Eur Heart J. 2021 Oct 21;42(40):4194
- [7] Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, Boriani G, Castella M, Dan GA, Dilaveris PE, Fauchier L, Filippatos G, Kalman JM, La Meir M, Lane DA, Lebeau JP, Lettino M, Lip GYH, Pinto FJ, Thomas GN, Valgimigli M, Van Gelder IC, Van Putte BP, Watkins CL; ESC Scientific Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021 Feb 1;42(5):373-498. doi: 10.1093/eurheartj/ehaa612. Erratum in: Eur Heart J. 2021 Feb 1;42(5):507. Erratum in: Eur Heart J. 2021 Feb 1;42(5):546-547. Erratum in: Eur Heart J. 2021 Oct 21;42(40):4194

- [8] Asad Z, Abbas M, Javed I, Korantzopoulos P, Stavrakis S. Obesity is associated with incident atrial fibrillation independent of gender: A meta-analysis. *J Cardiovasc Electrophysiol*. 2018 May;29(5):725-732
- [9] C.X. Wong, T. Sullivan, M.T. Sun, et al. Obesity and the risk of incident, post-operative, and post-ablation atrial fibrillation. *JACC EP*, 2015.
- [10] Magnani JW, Hylek EM, Apovian CM. Obesity begets atrial fibrillation: A contemporary summary. *Circulation*. 2013; 128: 401–405
- [11] Mills KT, Bundy JD, Kelly TN, Reed JE, Kearney PM, Reynolds K, Chen J, He J. Global disparities of hypertension prevalence and control: asystematic analysis of population-based studies from 90 countries. *Circulation*. 2016
- [12] Nabauer M, Gerth A, Limbourg T, Schneider S, Oeff M, Kirchhof P, Goette A, Lewalter T, Ravens U, Meinertz T, Breithardt G, Steinbeck G. The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management. *Europace*. 2009;11:423–434
- [13] Benjamin EJ, Levy D, Vaziri SM, D’Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart study. *JAMA*. 1994;271:840–844.
- [14] Huxley RR, Lopez FL, Folsom AR, Agarwal SK, Loehr LR, Soliman EZ, Macle hose R, Konety S, Alonso A. Absolute and attributable risks of atrial fibrillation in relation to optimal and borderline risk factors: the Atherosclerosis Risk in Communities (ARIC) study. *Circulation*. 2011;123:1501–1508
- [15] Lip GY, Andreotti F, Fauchier L, Huber K, Hylek E, Knight E, Lane D, Levi M, Marín F, Palareti G, Kirchhof P; European Heart Rhythm Association. Bleeding risk assessment and management in atrial fibrillation patients. Executive summary of a position document from the European Heart Rhythm Association [EHRA], endorsed by the European Society of Cardiology [ESC] working group on thrombosis. *Thromb Haemost*. 2011;106:997–1011
- [16] Ho LY, Siu CW, Yue WS, Lau CP, Lip GY, Tse HF. Safety and efficacy of oral anticoagulation therapy in Chinese patients with concomitant atrial fibrillation and hypertension. *J Hum Hypertens*. 2011;25:304–310
- [17] Chiang CE, Naditch-Brûlé L et al, Murin, J, Goethals, M, Inoue, H, O’Neill, J, Silva-Cardoso, J, Zharinov, O, Gamra, H, Alam, S, Ponikowski, P, Lewalter, T, Rosenqvist, M, Steg, PG. Distribution and risk profile of paroxysmal, persistent, and permanent atrial fibrillation in routine clinical practice: insight from the real-life global survey evaluating patients with atrial fibrillation international registry. *Circ Arrhythm Electrophysiol*. 2012;5:632–639
- [18] Dublin S, Glazer NL, Smith NL, Psaty BM, Lumley T, Wiggins KL, Page RL, Heckbert SR. Diabetes mellitus, glycemic control, and risk of atrial fibrillation. *J Gen Intern Med*. 2010; 25:853–858
- [19] Meijers JCM, Holleman F, Hermanides J, Lemkes BA, Devries JH, Hoekstra JBL. Hyperglycemia: a prothrombotic factor? *J Thromb Haemost*. 2010; 8:1663–1669; Watson T, Shantsila E, Lip GY. Mechanisms of thrombogenesis in atrial fibrillation: Virchow’s triad revisited. *Lancet*. 2009; 373:155–166
- [20] Lip, GY, Nieuwlaat, R, Pisters, R, Lane, DA, Crijns, HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. *Chest*. 2010;137:263–272
- [21] Fangel MV, Nielsen PB, Kristensen JK, Larsen TB, Overvad TF, Lip GYH, Jensen MB. Glycemic Status and Thromboembolic Risk in Patients With Atrial Fibrillation and Type 2 Diabetes Mellitus: A Danish Cohort Study. *Circ Arrhythm Electrophysiol*. 2019 May;12(5)
- [22] Kannel WB, Dawber TR, Friedman GD, Glennon WE, Mcnamara PM. Risk factors in coronary heart disease. An evaluation of several serum lipids as predictors of coronary heart disease; the Framingham study. *Ann Intern Med* 1964;61:888–899
- [23] Wern Yew Ding, Majd B Protty, Ian G Davies, Gregory Y H Lip, Relationship between lipoproteins, thrombosis, and atrial fibrillation, *Cardiovascular Research*, Volume 118, Issue 3, February 2022, Pages 716–731
- [24] Mora S, Akinkuolie AO, Sandhu RK, Conen D, Albert CM. Paradoxical association . of lipoprotein measures with incident atrial fibrillation. *Circ Arrhythm Electrophysiol* . 2014;7:612–619
- [25] Khovidhunkit W, Kim M-S, Memon RA, Shigenaga JK, Moser AH, Feingold KR, Grunfeld C. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. *J Lipid Res* 2004; 45:1169–1196
- [26] Tsai CT, Chang SH, Chang SN, Hwang JJ, Wu CK, Wang YC, Tseng CD, Yeh HM, Lai LP, Chiang FT, Lin JL. Additive effect of the metabolic syndrome score to the conventional CHADS₂ score for the thromboembolic risk stratification of patients with atrial fibrillation. *Heart Rhythm*. 2014 Mar;11(3):352-7

- [27] Kezerle L, Tsadok MA, Akriv A, Senderey AB, Bachrach A, Leventer-Roberts M, Haim M. Pre-Diabetes Increases Stroke Risk in Patients With Nonvalvular Atrial Fibrillation. *J Am Coll Cardiol*. 2021 Feb 23;77(7):875-884
- [28] Alwafi, H., Alotaibi, B., Naser, A. Y., Salawati, E., Qadus, S., Sweiss, K., Dairi, M. S., Hassouneh, L., Aldalameh, Y., & Samannodi, M. (2021). The safety and efficacy of the use of oral anticoagulant medications in patients with diabetes mellitus: A systematic review. *Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society*, 29(12), 1374–1382
- [29] Wallace JL, Reaves AB, Tolley EA, Oliphant CS, Hutchison L, Alabdan NA, Sands CW, Self TH. Comparison of initial warfarin response in obese patients versus non-obese patients. *J Thromb Thrombolysis*. 2013 Jul;36(1):96-101
- [30] T.-F. Wang, M. Carrier, How I treat obese patients with oral anticoagulants, *Blood* 135 (12) (2020) 904–911
- [31] Briasoulis A, Mentias A, Mazur A, Alvarez P, Leira EC, Vaughan Sarrazin MS. Comparative Effectiveness and Safety of Direct Oral Anticoagulants in Obese Patients with Atrial Fibrillation. *Cardiovasc Drugs Ther*. 2021 Apr;35(2):261-272
- [32] Navarro-Almenzar B, Cerezo-Manchado JJ, García-Candel F. Real life behaviour of direct oral anticoagulants in patients with nonvalvular atrial fibrillation and morbid obesity. *Int J Cardiol Heart Vasc*. 2021 Nov 11;37:100913
- [33] Barakat AF, Jain S, Masri A, Alkukhun L, Senussi M, Sezer A, Wang Y, Thoma F, Bhonsale A, Saba S, Mulukutla S. Outcomes of Direct Oral Anticoagulants in Atrial Fibrillation Patients Across Different Body Mass Index Categories. *JACC Clin Electrophysiol*. 2021 May;7(5):649-658.
- [34] Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, Haeusler KG, Oldgren J, Reinecke H, Roldan-Schilling V, Rowell N, Sinnaeve P, Collins R, Camm AJ, Heidbüchel H; ESC Scientific Document Group. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. *Eur Heart J*. 2018 Apr 21;39(16):1330-1393
- [35] Brar T, Chua D. Direct-Acting Oral Anticoagulant Choice for Stroke Prevention in Obese Patients With Atrial Fibrillation. *Can J Cardiol*. 2021 Sep;37(9):1489-1492.
- [36] Wiethorn, E.E., Bell, C.M. & Wiggins, B.S. Effectiveness and Safety of Direct Oral Anticoagulants in Patients with Nonvalvular Atrial Fibrillation and Weighing \geq 120 Kilograms versus 60–120 Kilograms. *Am J Cardiovasc Drugs* 21, 545–551 (2021)